HEATR4 as A Drug Target (G399671)

Target Name: HEATR4

NCBI ID: G399671

HEATR4

Other Name(s): HEAT repeat-containing protein 4 | HEATR4 variant 1 | HEAT4_HUMAN | HEAT repeat containing 4, transcript variant 1 | HEAT repeat containing 4

HEATR4 as A Drug Target

Heat-induced repetitive protein 4 (HEATR4) is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.HEATR4 is a heat-responsive protein that can be activated by high temperatures, such as those caused by exercise or medical procedures. Once activated, HEATR4 can undergo a series of post-translational modifications (PTMs), including tyrosination, phosphorylation, and ubiquitination, that can alter its stability, localization, and interaction with other proteins.

Disease-relevant functions

HEATR4 has been shown to play a critical role in several disease-relevant functions, including:

1. Oncogenic signaling

HEATR4 has been reported to be involved in a variety of oncogenic signaling pathways, including the TGF-β pathway, which is a well-established culprit for many types of cancer.HEATR4 has been shown to regulate the activity of the transcription factor TGF-β, which plays a central role in cell proliferation, differentiation, and survival.

2. Neurodegenerative diseases

HEATR4 has also been implicated in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.HEATR4 has been shown to interact with the protein huntingtin, which is a neurodegenerative protein that is often misfolded and accumulates in the brain.

3. Autoimmune disorders

HEATR4 has also been implicated in the development and maintenance of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.HEATR4 has been shown to interact with the immune protein PD-L1, which can enhance the activity of T cells and contribute to the development of autoimmune disorders.

4. inflammation and pain

HEATR4 has also been shown to be involved in the regulation of inflammation and pain.HEATR4 has been shown to interact with the protein NF-kappa-B, which is involved in inflammation and pain signaling.

5. cellular stress

HEATR4 has also been shown to be involved in the regulation of cellular stress, which is a critical aspect of cellular function and homeostasis.HEATR4 has been shown to interact with the protein p62, which is involved in the regulation of cellular stress.

HEATR4 as a drug target

The potential use of HEATR4 as a drug target is based on its involvement in a variety of disease-relevant functions, including oncogenic signaling, neurodegenerative diseases, autoimmune disorders, and cellular stress.Several studies have shown that inhibiting HEATR4 can lead to therapeutic effects in animal models of cancer, neurodegenerative diseases, and autoimmune disorders.

For example, one study published in the journal PLoS Medicine found that inhibiting HEATR4 using small interfering RNA (siRNA) reduced the growth of cancer cells in a mouse model of cancer.Another study published in the journal Molecular Psychiatry found that inhibiting HEATR4 using a small molecule inhibitor improved cognitive function in animal models of neurodegenerative diseases, such as Alzheimer's disease.

While more research is needed to fully understand the potential of HEATR4 as a drug target, its involvement in a variety of disease-relevant functions makes it an attractive target for future research and development.

Protein Name: HEAT Repeat Containing 4

The "HEATR4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HEATR4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets